The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study of LM-302, an anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer.
 
Chunmei Bai
No Relationships to Disclose
 
Junli Xue
No Relationships to Disclose
 
Yi Zheng
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Fuxiang Zhou
No Relationships to Disclose
 
Yiyi Yu
No Relationships to Disclose
 
Yuping Sun
Honoraria - AstraZeneca; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - Pfizer; Roche
 
Ligang Xing
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Jinhua Wen
No Relationships to Disclose
 
Jianping Xiong
No Relationships to Disclose
 
Heshui Wu
No Relationships to Disclose
 
Xiuli Yang
No Relationships to Disclose
 
Lixin Wan
No Relationships to Disclose
 
Shiwei Guo
No Relationships to Disclose
 
Rusen Zhao
No Relationships to Disclose
 
Zhizhen Zhu
No Relationships to Disclose
 
Zhihua Gong
Employment - LaNova Medicines Limited
 
Jin Li
No Relationships to Disclose